Craniopharyngioma, Child clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 1-39
The current study assesses the tolerability and efficacy of combination therapy with PD-1 (nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young adults with craniopharyngioma.
Our lead scientists for Craniopharyngioma, Child research studies include Sabine Mueller, MD, PhD, MAS.